TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacoinvasive Therapy With Prourokinase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 75 years or younger, symptom onset 6 h or less before randomization, intention to undertake primary PCI, ST-segment elevation of 2 mm or more in two anterior leads or of 1 mm or more in two inferior leads if they had ST-segment elevation, or new left bundle-branch block.~Exclusion Criteria:~* expected arrival at the catheterization laboratory less than 1 h or more than 3 h after randomization, anticipated problems with vascular access, previous enrollment to other studies, and the usual contraindications to thrombolytic therapy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- primary PCI (Type: PLACEBO_COMPARATOR): None
- prouk-PCI (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Association Between Smoking, Brain Activity, Genes, and ADHD

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Smokers with ADHD~   * Cigarette smoking for the last year~  * ADHD diagnosis~2. Nonsmokers with ADHD~   * No history of regularly smoking cigarettes~  * ADHD diagnosis~3. Normative control smokers~   * Cigarette smoking for the last year~  * No history and diagnosis of ADHD~4. Normative control nonsmokers~   * No history of regularly smoking cigarettes~  * No history and diagnosis of ADHD~Exclusion Criteria:~* Children under the age of 18~* Adults above the age of 45~* Pregnancy or planning to become pregnant~* Any major medical illness~* Any mental disorders that require medication (except stimulant medication)~* Any contraindications to fMRI scanning~* Not speaking English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Smokers with ADHD (Type: None): Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
- Nonsmokers with ADHD (Type: None): Nonsmokers with ADHD participated in one condition.
- Control smokers (Type: None): Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
- Control nonsmokers (Type: None): Control nonsmokers participated in one condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Closed-loop Double-vasopressor Automated System to Treat Hypotension During Spinal Anaesthesia for Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 21-45 years old,~* weight 40-90 kg,~* height 145-170 cm~Exclusion Criteria:~* contraindications to spinal anaesthesia,~* allergy to drugs used in the study, and~* those with uncontrolled medical conditions such as hypertension, diabetes mellitus, and cardiovascular disease

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- vasopressor delivery automated system (Type: EXPERIMENTAL): vasopressor delivery automated system that administered phenylephrine and ephedrine based on data from continuous non-invasive hemodynamic monitor
- manual vasopressor delivery (Type: ACTIVE_COMPARATOR): manual bolus that delivered phenylephrine and ephedrine based on data from non-invasive intermitted blood pressure monitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: What Treatment Works for Children With Selective Mutism?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children with a clinical diagnosis of Selective Mutism (SM)~Exclusion Criteria:~* Children with Mental Retardation (IQ\<50)~* Children with Pervasive Developmental Disorder (PDD)~* Children with SM in active treatment~* Children with SM on medication~* Children whose parents are non-Norwegian speaking

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- 1 Behavioral intervention (Type: OTHER): Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* chronic active ulcerative pancolitis~* course more than 4 months~* clinical index rachmilewitz 7 or more~* endoskopic index 7 or more~Exclusion Criteria:~* steroids in the last 4 weeks~* immunosuppressants in the last 4 weeks~* use of topical klymsa~* pregnancy~* fulminant course~* infectious colitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Malignancies that are refractory to or intolerant of established therapy known to provide clinical benefit. Patients must not be candidates for anti-tumor regimes known to provide clinical benefit.~2. All patients must have evidence of progressive disease on study entry. Previously untreated patients who are not chemotherapy candidates on Arm 2 may have advanced disease (without clear progression). There is no upper limit on the number of prior treatments provided that all inclusion criteria are met, and exclusion criteria are not met.~Exclusion Criteria~1. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤2 weeks prior to cycle 1 day 1 and mitomycin C and radioimmunotherapy 6 weeks prior to cycle 1 day 1.~2. Patients with active graft versus host disease after allogeneic stem cell transplantation. At least 3 months must have elapsed since completion of allogeneic stem cell transplantation except for patients with AML, where at least 2 months must have elapsed;~3. Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen);~4. Patients with active CNS malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months. Patient with malignant cells in their cerebrospinal fluid (CSF) without CNS symptom may be included.~5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea.~6. Grade ≥2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1).~7. Macular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity.~8. In the opinion of the investigator, patients who are significantly below their ideal body weight.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- selinexor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
General Inclusion Criteria for School-Aged Study Component:~* Male and female adolescents from the Boston area who are between the ages of 10 and 19 (inclusive);~* Have a parent or legal guardian who is able and willing to provide written informed consent for the active study phase (if under the age of 18);~* Competent and willing to provide written informed assent for the active study phase (if under the age of 18);~* Competent and able to provide written informed consent (if age 18 or older)~* Able to communicate in English language~* Able to commit to 9 study visits in approximately 60 days~* No severe developmental delays (including, but not limited to, Autism Spectrum Disorder, Intellectual Disability, and Down Syndrome)~* Able to safely participate in the protocol and appropriate for outpatient level of care~Cannabis-Using Group Inclusion Criteria:~* Use of cannabis at least once per week on most weeks~* Cannabis use reported within 7 days of both baseline visits~* No immediate plan to discontinue cannabis use~Non-Using Group Inclusion Criteria:~* Use of cannabis less than 5 times in lifetime~* No cannabis use in the past year~* No cannabis use before age 16~Exclusion Criteria for School-Aged Study Component~- Passive consent for initial school-wide assessment withdrawn by parent or legal guardian or written parental consent not provided prior to screening

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Abstinent (Type: ACTIVE_COMPARATOR): This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
- Monitoring (Type: NO_INTERVENTION): This group of cannabis users are not asked to change their cannabis use behavior.
- Non-Users (Type: NO_INTERVENTION): This is a group of adolescents with little to no cannabis use history and is non-randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female at least 9 years of age and older.~* Written and verbal informed consent must be obtained. Participants less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if participant reaches age of consent during the study they should be re-consented at the next study visit).~* Participants must be willing to comply with study instructions and return to the study center for required visits. Participants under the age of consent must be accompanied by the parent or legal guardian at the time of assent/consent signing.~* If a cleanser, moisturizer or sunscreen is needed during the study, participants must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the participant wears makeup they must agree to use non-comedogenic makeup.~Key Exclusion Criteria:~* Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.~* Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis.~* Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.~* Participants with a facial beard or mustache that could interfere with the study assessments.~* History of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure, including known sensitivities to any dosage form of tretinoin.~* Participants who are unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function.~* Participants with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the participant's safety while participating in the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-121 Lotion (Type: EXPERIMENTAL): IDP-121 lotion (tretinoin 0.05 percent \[%\]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
- IDP-121 Vehicle Lotion (Type: PLACEBO_COMPARATOR): IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female participants ≥1 years old at Visit 1.~* Participants and/or a legally acceptable representative/parent/legal guardian are willing and able to comply with all scheduled visits, vaccination plan, and other study procedures including completion of the e-diary for 7 days for participants after each of 3 vaccinations.~* Participants and/or a legally acceptable representative/parent/legal guardian must be able to be contacted by telephone during study participation.~* Participants and/or a legally acceptable representative/parent/legal guardian are capable of giving signed informed consent.~Exclusion Criteria:~* Major known congenital malformation or serious chronic disorder.~* Known history of TBEV infection.~* Known history of other flavivirus infection (eg, dengue fever, yellow fever, JEV, West Nile virus).~* Known history of infection with HIV, HCV, or HBV.~* Immunocompromised participants with known or suspected immunodeficiency.~* History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention.~* Previous vaccination with any licensed or investigational TBE vaccine, or planned receipt of other flavivirus vaccines apart from JEV vaccine (eg, yellow fever, dengue fever) during the study. Administration of JEV vaccine is prohibited during participation.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ≥16 Years Old (Type: EXPERIMENTAL): TBE vaccine 0.5 mL (intramuscular injection).
- 1 to <16 Years Old (Type: EXPERIMENTAL): TBE vaccine 0.25ｍL (intramuscular injection).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed relapsed B-cell non-Hodgkin's lymphoma (NHL)~  * Diffuse large cell B-cell lymphoma~ * Grade III follicular center-cell lymphoma~ * Primary mediastinal B-cell lymphoma~* CD20 positive~* First relapse after doxorubicin containing regimen~* Documented remission of at least 3 months after first-line chemotherapy~* No Epstein-Barr virus post-transplantation lymphoproliferative disorder~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* 18 to 65~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* No hepatic dysfunction~* Bilirubin less than 2.5 times upper limit of normal (ULN)~* Transaminases less than 2.5 times ULN~Renal:~* No renal dysfunction~* Creatinine less than 2.0 mg/dL OR~* Creatinine clearance greater than 40 mL/min~Cardiovascular:~* No severe cardiac dysfunction~* No New York Heart association class II-IV heart disease~Pulmonary:~* No severe pulmonary dysfunction~* Vital capacity or diffusion capacity at least 70% predicted unless related to NHL involvement~Other:~* No active uncontrolled infection~* HIV negative~* No intolerance to exogenous protein administration~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 1 month since prior immunotherapy~Chemotherapy:~* See Disease Characteristics~* At least 1 month since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 1 month since prior radiotherapy~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who was diagnosed with hepatocellular carcinoma, and was accompanied by impossible for radical treatment in disease period or do not reaction for local treatment, and the first time for sorafenib injection.~* Standard of hepatocellular carcinoma diagnosis (2014, The Korean Liver Cancer Association)~  1. Suitable on hepatocellular carcinoma pathologically~ 2. Hepatic nodule size over 1 cm on high-risk patients(hepatitis B virus positive, hepatitis C virus positive and liver cirrhosis) that identified by ultrasonography : In the case of suitable on hepatocellular carcinoma on over in one or two more dynamic contrast enhanced CT, dynamic contrast enhanced MRI, or MRI with Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid(Gd-EOB-DTPA)~ 3. Hepatic nodule size under 1 cm on high-risk patients that identified by ultrasonography : serum Alpha-fetoprotein(AFP) elevated over normal range constantly when hepatitis activity was restrained, and the case of suitable on hepatocellular carcinoma on over in two more the above image diagnoses~Exclusion Criteria:~* Unsuitable on inclusion criteria~* Patient who has had systemic anticancer therapy before (including sorafenib)~* Patient who is receiving another treatment to hepatocellular carcinoma recent 3 weeks (allow to local treatment of metastasis lesion only)~* Pregnant or Breastfeeding~* Urea cream contraindication patient (Acute eczema, Inflammatory dermatopathy and Hypersensitivity on Urea and Methylparaben)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Urea cream 20% (Type: EXPERIMENTAL): 144 patients spread urea cream (urea 20%)
- Placebo (Type: PLACEBO_COMPARATOR): 144 patients spread placebo cream (urea 0%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 21 to 70, You are a man or non-pregnant woman~Exclusion Criteria:~* Have a history of type I diabetes~* You are on a weight loss program with ongoing weight loss or taking weight loss medications~* You have a history of minor surgery~* You have received investigational drugs within 8 weeks of study start~* You have hepatitis B or C

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete